Levonorgestrel 1.5 mg and 0.75 mg, oral emergency contraceptive

Monitoring communication

28 February 2014

The TGA, in conjunction with the New Zealand therapeutic goods regulator MedSafe, is reviewing recent information that suggests levonorgestrel may not be effective for women who weigh more than 70 kg.

Levonorgestrel (marketed in Australia under the brand names NorLevo-1, NorLevo, Postinor and Levonelle), taken as a 1.5 mg tablet or two 0.75 mg tablets, is used as an oral emergency contraceptive within 72 hours of unprotected sexual intercourse.

Consumers are advised that, irrespective of the weight of the woman taking it, levonorgestrel may not prevent pregnancy in every case. The sooner you take emergency contraceptive, the more likely it is that it will work.

The TGA will provide further information for consumers and health professionals once the review is complete.

In the meantime, if you have any questions or concerns about levonorgestrel, speak to your health professional.

Reporting problems

Consumers and health professionals are encouraged to report problems with medicines or vaccines. Your report will contribute to the TGA’s monitoring of these products.

The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.